Oculis Holding AG (OCS) Change in Accured Expenses (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Change in Accured Expenses came in at $1.1 million in Q1 2026, up 436.05% year-on-year from $209877.6 in Q1 2025, and up 514.37% quarter-over-quarter from -$271503.8 in Q4 2025.
Oculis Holding AG (OCS) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Oculis Holding AG's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 436.05% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was -$832893.9, a 105.56% decrease from a year earlier, with the FY2025 full-year figure at -$2.3 million, down 121.96% from the prior year.
- Change in Accured Expenses grew to $1.1 million in Q1 2026 per OCS's latest filing, from -$271503.8 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $6.7 million in Q2 2024 and bottomed at -$5.8 million in Q1 2023.
- The 5-year median for Change in Accured Expenses is $890610.0 (2023), against an average of $275292.4.
- Across the five-year window, Change in Accured Expenses plunged 142.73% in 2025 and surged 436.05% in 2026, its largest moves.
- Year by year, Change in Accured Expenses stood at $2.5 million in 2022, then plunged by 64.62% to $890610.0 in 2023, then jumped by 312.08% to $3.7 million in 2024, then sank by 107.4% to -$271503.8 in 2025, then surged by 514.37% to $1.1 million in 2026.
- Per Business Quant, the three latest OCS Change in Accured Expenses figures stand at $1.1 million (Q1 2026), -$271503.8 (Q4 2025), and $1.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -16.74 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | -176.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.13 Mn |
| Mar 31, 2026 | 1.13 Mn |
| Dec 31, 2025 | -271,503.84 |
| Dec 31, 2025 | -271,503.84 |
| Sep 30, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | -2.86 Mn |
| Jun 30, 2025 | -2.86 Mn |
| Mar 31, 2025 | -334,787.41 |
| Mar 31, 2025 | -334,787.41 |
| Dec 31, 2024 | 3.67 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Jun 30, 2024 | 6.69 Mn |
| Jun 30, 2024 | 6.69 Mn |
| Mar 31, 2024 | -4.76 Mn |
| Mar 31, 2024 | -4.76 Mn |
| Dec 31, 2023 | 890,610.03 |
| Dec 31, 2023 | 890,610.03 |